Standard heparin (UFH) versus certoparin (LMWH)
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Heparin-Induced Thrombocytopenia
Conditions
Heparin-Induced Thrombocytopenia
Trial Timeline
Jan 1, 2003 → Nov 1, 2005
NCT ID
NCT00196417About Standard heparin (UFH) versus certoparin (LMWH)
Standard heparin (UFH) versus certoparin (LMWH) is a approved stage product being developed by Novartis for Heparin-Induced Thrombocytopenia. The current trial status is unknown. This product is registered under clinical trial identifier NCT00196417. Target conditions include Heparin-Induced Thrombocytopenia.
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00196417 | Approved | UNKNOWN |
Competing Products
1 competing product in Heparin-Induced Thrombocytopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban | Bristol Myers Squibb | Phase 2 | 27 |